Chinese regulators approved a coin‑sized, wireless brain‑computer interface (BCI) made by Shanghai‑based Neuracle Medical Technology for commercial use in patients with spinal cord injuries—the first national clearance of a BCI for broad clinical deployment. The device records cortical signals and decodes them to control external devices, promising new rehabilitative options for people with paralysis. The approval positions Neuracle as an early entrant in the commercial BCI market and may accelerate clinical adoption in China, where regulators moved faster than some Western counterparts. The clearance also intensifies competition with U.S. and European BCI developers—companies such as Neuralink, Synchron and Paradromics—by shifting part of the commercialization timeline forward in a major market.